Istiratumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | IGF1R, ErbB3 |
| Clinical data | |
| Other names | MM-141 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C8802H13532N2392O2796S58 |
| Molar mass | 199458.51 g·mol−1 |
Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.
It is in development by Merrimack Pharmaceuticals (In the US) and was awarded orphan drug status for pancreatic cancer.